Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines - PubMed (original) (raw)

. 2000 May 15;60(10):2589-93.

M Maliepaard, A C Pijnenborg, M A van Gastelen, M C de Jong, A B Schroeijers, D M van der Kolk, J D Allen, D D Ross, P van der Valk, W S Dalton, J H Schellens, R J Scheper

Affiliations

• PMID: 10825126

Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines

G L Scheffer et al. Cancer Res. 2000.

Abstract

Tumor cells may display a multidrug resistant phenotype by overexpression of ATP-binding cassette transporters such as multidrug resistance (MDRI) P-glycoprotein, multidrug resistance protein 1 (MRP1), and breast cancer resistance protein (BCRP). The presence of BCRP has thus far been reported solely using mRNA data. In this study, we describe a BCRP-specific monoclonal antibody, BXP-34, obtained from mice, immunized with mitoxantrone-resistant, BCRP mRNA-positive MCF-7 MR human breast cancer cells. BCRP was detected in BCRP-transfected cells and in several mitoxantrone- and topotecan-selected tumor cell sublines. Pronounced staining of the cell membranes showed that the transporter is mainly present at the plasma membrane. In a panel of human tumors, including primary tumors as well as drug-treated breast cancer and acute myeloid leukemia samples, BCRP was low or undetectable. Extended studies will be required to analyze the possible contribution of BCRP to clinical multidrug resistance.

PubMed Disclaimer

Similar articles

• Flow cytometric analysis of breast cancer resistance protein expression and function.
  Minderman H, Suvannasankha A, O'Loughlin KL, Scheffer GL, Scheper RJ, Robey RW, Baer MR. Minderman H, et al. Cytometry. 2002 Jun 1;48(2):59-65. doi: 10.1002/cyto.10111. Cytometry. 2002. PMID: 12116365
• Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
  Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S. Shiozawa K, et al. Int J Cancer. 2004 Jan 1;108(1):146-51. doi: 10.1002/ijc.11528. Int J Cancer. 2004. PMID: 14618629
• Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
  Schellens JH, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW, Beijnen JH, Schinkel AH. Schellens JH, et al. Ann N Y Acad Sci. 2000;922:188-94. doi: 10.1111/j.1749-6632.2000.tb07037.x. Ann N Y Acad Sci. 2000. PMID: 11193894
• [Drug-resistant proteins in breast cancer: recent progress in multidrug resistance].
  Wu DL, Huang F, Lu HZ. Wu DL, et al. Ai Zheng. 2003 Apr;22(4):441-4. Ai Zheng. 2003. PMID: 12704006 Review. Chinese.
• Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
  Doyle L, Ross DD. Doyle L, et al. Oncogene. 2003 Oct 20;22(47):7340-58. doi: 10.1038/sj.onc.1206938. Oncogene. 2003. PMID: 14576842 Review.

Cited by

• Expression levels of the ABCG2 multidrug transporter in human erythrocytes correspond to pharmacologically relevant genetic variations.
  Kasza I, Várady G, Andrikovics H, Koszarska M, Tordai A, Scheffer GL, Németh A, Szakács G, Sarkadi B. Kasza I, et al. PLoS One. 2012;7(11):e48423. doi: 10.1371/journal.pone.0048423. Epub 2012 Nov 15. PLoS One. 2012. PMID: 23166586 Free PMC article.
• The role of half-transporters in multidrug resistance.
  Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T. Bates SE, et al. J Bioenerg Biomembr. 2001 Dec;33(6):503-11. doi: 10.1023/a:1012879205914. J Bioenerg Biomembr. 2001. PMID: 11804192 Review.
• Multidrug resistance related molecules in human and murine lung.
  Scheffer GL, Pijnenborg AC, Smit EF, Müller M, Postma DS, Timens W, van der Valk P, de Vries EG, Scheper RJ. Scheffer GL, et al. J Clin Pathol. 2002 May;55(5):332-9. doi: 10.1136/jcp.55.5.332. J Clin Pathol. 2002. PMID: 11986335 Free PMC article.
• Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation.
  Boonstra R, Timmer-Bosscha H, van Echten-Arends J, van der Kolk DM, van den Berg A, de Jong B, Tew KD, Poppema S, de Vries EG. Boonstra R, et al. Br J Cancer. 2004 Jun 14;90(12):2411-7. doi: 10.1038/sj.bjc.6601863. Br J Cancer. 2004. PMID: 15150577 Free PMC article.
• The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.
  Bhullar J, Natarajan K, Shukla S, Mathias TJ, Sadowska M, Ambudkar SV, Baer MR. Bhullar J, et al. PLoS One. 2013 Aug 14;8(8):e71266. doi: 10.1371/journal.pone.0071266. eCollection 2013. PLoS One. 2013. PMID: 23967177 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • Cellosaurus - a cell line knowledge resource
  • NCI CPTC Antibody Characterization Program